AbbVie Inc (ABBV)
Receivables turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 54,318,000 | 58,054,000 | 56,197,000 | 45,804,000 | 33,266,000 |
Receivables | US$ in thousands | 11,155,000 | 11,254,000 | 9,977,000 | 8,822,000 | 5,428,000 |
Receivables turnover | 4.87 | 5.16 | 5.63 | 5.19 | 6.13 |
December 31, 2023 calculation
Receivables turnover = Revenue ÷ Receivables
= $54,318,000K ÷ $11,155,000K
= 4.87
The receivables turnover ratio for Abbvie Inc has shown a general decreasing trend over the past five years. The ratio decreased from 6.13 in 2019 to 4.87 in 2023. This indicates that the company took longer to collect outstanding receivables in 2023 compared to previous years. While a decreasing trend may indicate potential issues with collecting receivables efficiently, it is essential to consider industry norms and company-specific factors before drawing definitive conclusions about the company's receivables management.
Peer comparison
Dec 31, 2023
Company name
Symbol
Receivables turnover
AbbVie Inc
ABBV
4.87
Abbott Laboratories
ABT
6.01
Alkermes Plc
ALKS
4.93
Amphastar P
AMPH
5.61
ANI Pharmaceuticals Inc
ANIP
2.80
Arcus Biosciences Inc
RCUS
29.25
Biomarin Pharmaceutical Inc
BMRN
3.75
Bristol-Myers Squibb Company
BMY
4.12
Catalent Inc
CTLT
4.76
Catalyst Pharmaceuticals Inc
CPRX
7.44
Collegium Pharmaceutical Inc
COLL
2.56